FDA is assessing the impact on supplies after a tornado damaged Pfizer’s sterile injectables plant in North Carolina. Fewer than 10 drugs rely solely on this plant for the U.S. market. The FDA is implementing mitigation measures for potential shortages, and Pfizer has strict inventory allocation to ensure equitable distribution. Healthcare systems facing difficulties obtaining drugs should contact their distributor or Pfizer. The American Hospital Association is closely monitoring the situation as some drugs were already on the FDA’s shortage list before the tornado.
FDA is currently assessing the potential impact on supplies following the damage caused by a tornado to Pfizer’s sterile injectables plant in North Carolina. While they do not anticipate any immediate significant supply disruptions, the FDA is collaborating with Pfizer to conduct a thorough assessment, and they will provide further updates as information becomes available.
Initial analysis indicates that there are fewer than 10 drugs exclusively sourced from this plant for the U.S. market. However, the FDA points out that some of these drugs have alternative formulations or sufficient stock in other Pfizer warehouses. For products that are at risk of shortage, the FDA has taken measures to mitigate the situation. They are actively seeking additional sources and encouraging other manufacturers to increase production capacity if necessary.
To ensure equitable distribution and prevent hoarding, Pfizer has implemented strict allocation measures for its inventory. Depending on contractual relationships for supplies, these measures may cause localized supply disruptions. The FDA advises healthcare systems experiencing difficulties in obtaining specific drugs to contact their distributor or Pfizer directly for assistance.
The American Hospital Association (AHA) is closely monitoring the situation, as several of the drugs produced at the affected plant were already on the FDA’s shortage list before the tornado incident.
